RxDoctor Payments Data

Brent Martinez, MD

Pulmonary Disease · Canton, OHNPI 1891172334

Payments from drug & device makers

$1,393in general payments, 2019–2025

Across 41 payments — averaging $33.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$273
  • AstraZeneca$220
  • Sanofi$184
  • GSK$158
  • Genentech USA, Inc.$120
  • Sanofi-aventis U.S. LLC$95
  • plus $343 from 9 others

What the payments were for

  • Food & beverage$1,24589%
  • Education$14811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,393 in reported general payments places this provider in the 45th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$92,421
Medicare patients
299
Services billed
866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter272$182,912
Spiriva RespimatTiotropium Bromide137$93,289
Stiolto RespimatTiotropium Br/Olodaterol Hcl107$61,013
Breo ElliptaFluticasone/Vilanterol79$41,227
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr73$33,489
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$32,612
SymbicortBudesonide/Formoterol Fumarate68$20,048
DuleraMometasone/Formoterol41$13,645
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate62$11,578
Wixela InhubFluticasone Propion/Salmeterol46$6,724
Albuterol Sulfate HfaAlbuterol Sulfate275$6,696
Varenicline Tartrate19$5,617
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$5,523
Arnuity ElliptaFluticasone Furoate12$3,220
BreynaBudesonide/Formoterol Fumarate22$3,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$158$260,848436 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$93$154,302244 claims
AstraZenecaBreztri Aerosphere, Symbicort$220$52,660120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →